

Boehringer Ingelheim Vetmedica, Inc., Welcomes Two New Leaders

Boehringer Ingelheim Vetmedica, Inc., (BIVI), recently welcomed two new executives. Mechtild Goerke recently joined BIVI as the new vice president of finance. Goerke has been with Boehringer Ingelheim (BI) for more than 20 years, previously working as the head of human pharmaceutical project evaluation development and licensing in the corporate division of finance and controlling with the financial oversight of international pipeline projects and licensing contracts. Prior to this, Goerke worked for Boehringer Ingelheim group of companies in Germany and France, in various controlling positions. She graduated with a degree in business economics and administration from the Albertus-Magnus University of Cologne/Germany.



Karen Roggeman joins the team in August as vice president of sales and marketing. Roggeman has been with BI since 2004. Prior to her role at BIVI, she served as the U.S. vice president of marketing, pipeline strategy and development, where her team led-US and global commercial strategy for BI's early human pharmaceutical pipeline products. Throughout her career, she has held various leadership roles within marketing, sales and business development in the US and internationally. Prior to joining BI, Roggeman was with Merck & Co., Inc., for 13 years. She is a graduate of the University of Arizona and holds a master's in business from the University of Southern California.

Goerke replaces Dana Leskova, and Roggeman replaces Tim Bettington, both of whom have accepted global positions within Boehringer Ingelheim (BI).

About Boehringer Ingelheim Vetmedica, Inc.

Boehringer Ingelheim Vetmedica, Inc., (BIVI) is the fifth largest animal health company in the U.S. and produces innovative vaccine and pharmaceutical products for the prevention and treatment of diseases in the swine, cattle, equine and companion animal markets. BIVI is the U.S. subsidiary of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other locations in Ames, Fort Dodge and Sioux Center, Iowa.

With more than 3,600 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about 1.13 billion euros in 2014. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 11% of net sales of the Animal Health business in R&D.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

For more information please visit www.bi-vetmedica.com